English | Español

Horizon Therapeutics
Patient Daily | May 7, 2023

Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Lupus Nephritis
Patient Daily | May 7, 2023

Horizon Therapeutics plc Ranks First in Patient Centricity and Integrity by Patient Advocacy Groups According to New PatientView Survey
Patient Daily | May 7, 2023

Horizon Therapeutics plc Announces Initiation of Phase 3 Clinical Trial in Japan Evaluating TEPEZZA® (teprotumumab-trbw) in Adults with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED)
Patient Daily | May 7, 2023

Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
Patient Daily | Apr 24, 2023

Horizon Therapeutics plc Announces UPLIZNA® (inebilizumab-cdon) Data in Neuromyelitis Optica Spectrum Disorder (NMOSD) to be Presented at the 2023 American Academy of Neurology (AAN) Annual Meeting
Patient Daily | Apr 24, 2023

Horizon Therapeutics plc and Massachusetts Institute of Technology (MIT) Solve Announce the Launch of the Third Annual Horizon Prize to Inspire Sustainable Solutions for Research and Care in the Rare Disease Community
Patient Daily | Apr 24, 2023

Horizon Therapeutics Announces Date of Irish Court Hearing to Sanction Scheme of Arrangement

Trending
Patient Daily | Aug 18, 2025

Medfluence Advisors’ Greg Caesar to open ASCENT 2025 with keynote on digital practice growth
+ Pharmaceuticals
Patient Daily | Aug 18, 2025

Patients Come First spokesperson on 340B rebate model: ‘This rebate model provides the oversight that 340B has needed for decades’
+ Pharmaceuticals
Patient Daily | Aug 21, 2025

PhRMA director of public affairs on 340B rebate model: "Positive first step toward addressing hospital abuse of the 340B program
Patient Daily | Aug 21, 2025

SoCal Breathe Free doctor on balloon sinuplasty: ‘The procedure itself is pretty quick and effectiveness is pretty high’